0001815903 false 0001815903 2021-12-22 2021-12-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

  

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 22, 2021

 

Petros Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

  

Delaware

(State or other
jurisdiction of
incorporation)

001-39752

(Commission
File Number)

85-1410058

(I.R.S. Employer

Identification No.)

 

1185 Avenue of the Americas, 3rd Floor

New York, New York 10036
(Address of principal executive offices)    (Zip code)

 

(973) 242-0005
(Registrant's telephone number, including area code)

 

Not applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 Under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on
which registered
Common Stock, par value $0.0001 per share PTPI The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

  

 

  

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Second Amendment to the Petros Pharmaceuticals, Inc. 2020 Omnibus Incentive Compensation Plan

 

On December 22, 2021, Petros Pharmaceuticals, Inc. (the “Company”) held its 2021 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders approved the Second Amendment to the Petros Pharmaceuticals, Inc. 2020 Omnibus Incentive Compensation Plan (the “Second Amendment”) to increase the aggregate number of shares available for the grant of awards by 1,521,654 shares, to a total of 2,600,000 shares. The Second Amendment was previously approved, subject to stockholder approval, by the Company’s Board of Directors (the “Board”), upon the recommendation of the Board’s Compensation Committee, on November 17, 2021.

 

Election of Five Directors

 

As previously reported in the Company’s definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on November 22, 2021 (the “2021 Proxy”), the terms of the Company’s directors were scheduled to expire at the Annual Meeting, and the Board nominated all five directors for re-election at the Annual Meeting.

 

At the Annual Meeting, John D. Shulman, Joshua N. Silverman, Bruce T. Bernstein, Gregory Bradley and Wayne R. Walker were elected as directors of the Board to serve for a term expiring at the Company’s 2022 annual meeting of stockholders.

 

For more information about the matters above see the Company’s 2021 Proxy, the relevant portions of which are incorporated herein by reference. The description of the Second Amendment and such portions of the 2021 Proxy are qualified in their entirety by reference to the full text of the Second Amendment, filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

At the Company’s Annual Meeting, holders of the Company’s common stock of a total voting power of 9,230,249 shares were present in person or represented by proxy. The matters submitted for a vote and the related results are set forth below.

 

  (1) Election of five directors to serve on our board of directors to serve for a term of one year or until their successors are elected and qualified:

 

Nominee   Votes For   Votes Against   Votes Abstaining   Broker Non-Votes
John D. Shulman   5,925,019   33,421   8,915   3,262,894
Joshua N. Silverman   5,891,944   69,196   6,215   3,262,894
Bruce T. Bernstein   5,931,436   29,704   6,215   3,262,894
Gregory Bradley   5,932,252   28,304   6,799   3,262,894
Wayne R. Walker   5,931,961   27,194   8,200   3,262,894

 

  (2) Approval of a proposed amendment to the Petros Pharmaceuticals, Inc. 2020 Omnibus Incentive Compensation Plan, as amended, to increase the aggregate number of shares available for the grant of awards by 1,521,654 shares, to a total of 2,600,000 shares:

 

Votes For   Votes Against   Votes Abstaining   Broker Non-Votes
5,861,427   85,051   20,877   3,262,894

 

 

 

 

  (3) Ratification of the appointment of EisnerAmper LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021:

 

Votes For   Votes Against   Votes Abstaining
9,179,711   36,783   13,755

 

  (4) Approval, on an advisory basis, of the compensation paid to our named executive officers:

 

Votes For   Votes Against   Votes Abstaining   Broker Non-Votes
5,887,405   66,413   13,537   3,262,894

 

  (5) Approval, on an advisory basis, of the frequency of future advisory votes on the compensation paid to our named executive officers:

 

1 year   2 years   3 years   Withheld/Abstained   Broker Non-Votes
5,878,685   8,835   30,971   48,864   3,262,894

 

For more information about the foregoing proposals, see the Company’s 2021 Proxy, the relevant portions of which are incorporated herein by reference.

 

The results reported above are final voting results. No other matters were considered or voted upon at the Annual Meeting.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

See the Exhibit Index below, which is incorporated by reference herein.

 

EXHIBIT INDEX

 

Exhibit Description
10.1 Second Amendment to the Petros Pharmaceuticals, Inc. 2020 Omnibus Incentive Compensation Plan
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    PETROS PHARMACEUTICALS, INC.
     
Date: December 23, 2021 By: /s/ Fady Boctor
    Name: Fady Boctor
    Title: President and Chief Commercial Officer

 

 

Exhibit 10.1

 

Second AMENDMENT TO
Petros Pharmaceuticals, Inc.
2020 Omnibus Incentive Compensation PLAN

 

This Second Amendment To Petros Pharmaceuticals, Inc. 2020 Omnibus Incentive Compensation Plan (this “Amendment”), effective as of December 22, 2021, is made and entered into by Petros Pharmaceuticals, Inc., a Delaware corporation (the “Company”). Terms used in this Amendment with initial capital letters that are not otherwise defined herein shall have the meanings ascribed to such terms in the Petros Pharmaceuticals, Inc. Omnibus Incentive Compensation Plan (the “Plan”).

 

RECITALS

 

WHEREAS, Section 17(a) of the Plan provides that the Board of Directors of the Company (the “Board”) may amend the Plan at any time and from time to time, provided that the Board shall not amend the Plan without stockholder approval if such approval is required in order to comply with the Code or any other applicable law, or to comply with the applicable stock exchange requirements;

 

WHEREAS, the Board desires to amend the Plan to increase the aggregate number of shares of Common Stock that may be issued under the Plan, as set forth in Section 4(a) of the Plan, by an additional 1,521,654 shares of Common Stock; and

 

WHEREAS, the Board intends to submit this Amendment to the Company’s stockholders for their approval in accordance with Section 17(a) of the Plan.

 

NOW, THEREFORE, in accordance with Section 17(a) of the Plan, the Company hereby amends the Plan as follows:

 

1.            Section 4(a) of the Plan is hereby amended by deleting said section in its entirety and substituting in lieu thereof the following new Section 4(a):

 

(a)            Shares Authorized. Subject to adjustment as described below in Sections 4(b) and 4(e), the maximum aggregate number of shares of Common Stock that may be issued or transferred under the Plan with respect to Awards made on and after the Effective Date shall be 2,600,000 shares. In addition, and subject to adjustment as described below in Sections 4(b) and 4(e), shares of Common Stock subject to outstanding Awards granted under the Plan before the Effective Date and shares of Common Stock subject to outstanding grants under the Prior Plans that terminate, expire or are cancelled, forfeited, exchanged or surrendered without having been exercised, vested or paid in shares after the Effective Date shall be added to the shares reserved under the Plan. The aggregate number of shares of Common Stock that may be issued or transferred under the Plan pursuant to Incentive Stock Options granted on and after the Effective Date shall not exceed 2,600,000 shares of Common Stock.

 

2.            Section 4(d)(i) of the Plan is hereby amended by deleting the number “1,078,346” and replacing it with the number “216,669”.

 

 

 

 

3.            This Amendment shall be effective on the date first set forth above.  In the event stockholder approval of this Amendment is not obtained within twelve (12) months of the date the Board approved this Amendment, the additional shares added to the Plan pursuant to this Amendment shall not be available for grant as Incentive Stock Options.

  

4.            Except as expressly amended by this Amendment, the Plan shall continue in full force and effect in accordance with the provisions thereof.

 

[Remainder of the Page Intentionally Left Blank; Signature Page Follows]

 

 

 

 

IN WITNESS WHEREOF, the Company has caused this Amendment to be duly executed as of the date first written above.

 

  Petros Pharmaceuticals, Inc.
   
   
  By: /s/ Fady Boctor
  Name: Fady Boctor
  Title: President and Chief Commercial Officer

 

Signature Page to
Second Amendment to
Petros Pharmaceuticals, Inc.
Omnibus Incentive Compensation Plan